Real-Time Real Talk by Dexcom

Dexcom
Real-Time Real Talk by Dexcom

Welcome to “Real-time real talk,” a podcast for healthcare providers who treat people with diabetes. Each month, tune in to expert-led discussions on topics such as continuous glucose monitoring (CGM), clinical evidence for Dexcom real-time CGM, how to set up and use CGM in your practice, and real-world experiences with the Dexcom G6 CGM System. Our goal is to help you better treat your patients with type 1 and type 2 diabetes using Dexcom CGM. Real-time real talk is intended for healthcare professionals in the US.

  1. FEB 26

    Type 2 Diabetes Management Through Glucose Tracking: How CGM Improves Patient Outcomes

    Welcome back to another episode of Real-Time Real Talk where this week, host Cher Pastore is joined by Dr Thomas Grace and Dr. William Polonsky to discuss the power of Continuous Glucose Monitoring (CGM) in managing type 2 diabetes. Continuous Glucose Monitoring has revolutionized the management of diabetes. At its core, diabetes management is about balancing blood glucose levels to avoid the serious complications associated with hyperglycaemia and hypoglycaemia. CGM technology provides both patients and healthcare professionals with real-time data on glucose levels, making it a powerful tool in this balancing act. In this episode Dr Grace and Dr Polonsky share their insights from their research, highlighting significant reductions in A1C levels and improvements in patient outcomes with the use of CGM. They highlight the clinical benefits of CGM for managing glucose levels and making informed dietary and lifestyle choices. Additionally, they discuss the psychological effects of CGM including increased engagement, empowerment, and reduced anxiety.  Dr Grace also introduces an exciting new product from Dexcom called Stelo, which will be an over the counter option for patients with type two diabetes (not on insulin), meaning that if your doctor is unwilling to write you a prescription for a Dexcom G7, you yourself can go to www.stelo.com and see if an over the counter product is appropriate for you.

    39 min
  2. JAN 8

    Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes

    Welcome back to another episode of Real-Time Real Talk. This week, host Cher Pastore is joined by Emily Cornelius, a Registered Dietitian, to discuss the science behind monitoring glucose levels in individuals with prediabetes and type 2 diabetes who are not on insulin as well as introducing a brand new product by Dexcom called Stelo.  Having faced challenges with dieting as a young adult, Emily discovered the importance of nutrition. This experience set her on a career path and a personal mission to help more women love the way they look, eat, and feel. Through her work, she focuses on helping exhausted dieters achieve their goals by addressing the root cause of weight gain (insulin resistance) while still enjoying the foods they love. She is also well-known across social media platforms, where she highlights creative ways to eat healthily without letting diet consume all their time.   In this episode, Emily shares her experience using continuous glucose monitoring (CGM) and how it has helped her clients with insulin resistance and weight loss. They discuss the impact of glucose sensors on behavior change, the importance of personalized nutrition plans, and the accessibility of glucose sensors without a prescription. They also highlight the benefits of using glucose sensors in managing prediabetes and making informed food and exercise choices.   Emily and Cher also look at the brand-new product from Dexcom, Stelo, a glucose biosensor indicated for people with type 2 diabetes or prediabetes. Stelo tracks glucose 24/7, revealing how food, exercise, and even sleep can affect glucose levels, helping you become a healthier you.   Visit www.stelo.com to find out more.

    28 min
  3. 07/23/2024

    Empowering Diabetes Care: Revolutionizing Hospital Discharge Planning with CGM Technology

    Welcome to another session of Real Time Real Talk!Host Cher Pastore speaks to guest, David Tulle who has worked for Dexcom for over 11 years, leading teams across the central Plains, in the mid south and US regions and is currently leading Dexcom’s hospital discharge program.David’s focus is a new approach: integrating Continuous Glucose Monitoring (CGM) systems, such as Dexcom's, into hospital discharge plans for better diabetes management. The conversation covers how the adoption of CGM systems, which provide real-time glucose data, is transforming transitional care strategies from hospital to home, and significantly improving patient outcomes.The second half of the discussion explores Dexcom's innovative initiative to incorporate CGM into hospital discharge plans, streamlining the transition from acute care to home management for patients diagnosed with diabetes. David and Cher discuss how this program provides education and critical tools to newly diagnosed diabetes patients, potentially reducing readmission rates, and offering insight into how Dexcom's initiative could address the need for better disease management strategies post-discharge. They also cover the technology and how it offers real-time insight into glucose levels, aiding patients in their decision making regarding diet, exercise, and medication. The episode also investigates how this strategic introduction into hospital discharge plans can ensure a seamless transition for patients back home, and play a vital role in the prevention of complications and fostering positive patient outcomes.Finally, Cher and David also discuss the collaborative benefits of this program, including how the integration of CGM into discharge planning can empower healthcare professionals to provide better care continuity. They look at why vulnerability in the healthcare system calls for the use of technologies like CGM and how Dexcom's strategy paves the way for a more holistic and technology-driven approach to diabetes management.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide: https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. For more information on the Dexcom Hospital Discharge program visit dexcomprovider.comDavid Tulle is an employee of Dexcom.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The...

    33 min
  4. 06/04/2024

    Clinical Accuracy in CGM and Why it Matters

    Welcome back to another episode of Real Time Real Talk where this week, host Cher Pastore is joined by Dr Jessica Castle and Dr Stayce Beck to discuss the meticulous process behind the formulation and execution of Continuous Glucose Monitoring (CGM) accuracy trials.The trio discuss the influence of rigorous trial design and transparency on the accuracy and reliability of CGM devices, particularly those developed by Dexcom. They highlight the importance of CGM research's credibility, strategies to minimize bias, and the essential role that regulatory bodies play in ensuring quality health research. The discussion also covers the dynamics of conflicts of interest, patient and healthcare provider education, and the significance of detailed metrics for evaluating CGM performance.Our expert panel also take us behind the scenes to reveal the meticulous work involved in creating and executing CGM studies that encompass different populations and conditions. You’ll hear discussions around key performance metrics in a CGM accuracy study, understanding why blood glucose monitor and CGM readings might not match and the explanation of relative difference and CGM accuracy.The conversation highlights the comprehensive journey towards ensuring users can trust their CGM readings, right from day one to real-world applications. Finally, listen as they walk us through the process of bringing transparency to CGM data analysis, alongside discussing the potential challenges and future of CGM device application in pediatric hospital discharge programs, probing into the potential barriers and challenges faced by healthcare providers and patients.   Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Jessica R. Castle, MD and Stayce E. Beck, PhD, MPH, are employees of Dexcom.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.   References:1. Castle JR, Beck SE. The Importance of Trial Design in Evaluating the Performance of Continuous Glucose Monitoring Systems: Details Matter. Journal of Diabetes Science and Technology. 2024 Feb 23   2. Clinical and Laboratory Standards Institute (CLSI). Performance Metrics for Continuous Interstitial Glucose Monitoring (CLSI Guideline POCT05). 2nd ed. Wayne, PA: CLSI; 2020.   3....

    33 min
  5. 03/20/2024

    Navigating Pregnancy with Diabetes: CGM Strategies for Success

    Tune in to the latest episode of Real Time Real Talk with your host Cher Pastore, MS, RD, CDCES, BC-ADM. In this episode we take a deep and insightful look at the ever-evolving landscape of Continuous Glucose Monitoring (CGM) systems specifically within pregnancy with our guest, Dr Kristin Castorino.  We explore in detail how this technology benefits pregnant patients with diabetes, focusing on the practicality of using devices like Dexcom G7 and how they aid both clinicians and patients in navigating this complex yet essential side of prenatal care.Get a first-hand perspective on the benefits, challenges and the road ahead in diabetes care as Cher and Kristin delve into how CGM systems make data interpretation easier. They also discuss the data abundance and the changes needed to mitigate the information overload it can often cause. Finally, Kristin discusses common misconceptions about CGM, the key role played by insurance coverage in the adoption of CGMs, and a look into the promising developments in the near future.From debunking myths and clarifying concerns about CGM to emphasizing how this technology feeds into a more integrated care environment, this is an episode you won't want to miss.Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes paper: https://pubmed.ncbi.nlm.nih.gov/38315503/Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.Kristin Castorino, MD is a paid spokesperson for Dexcom.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software....

    28 min
  6. 02/14/2024

    Exercise, Type 1 Diabetes and CGM: Cutting-Edge Insights from Recent Studies

    In another episode of Real Time Real Talk, host Cher Pastore invites Dr Dessi P. Zaharieva, PhD, CEP, CDCES to discuss all things diabetes.   Dessi completed her PhD in Kinesiology & Health Science at York University under the supervision of leading diabetes researcher, Dr. Michael Riddell. She is currently working with Dr. David Maahs and the University of Stanford team to improve clinical outcomes in youth with type 1 diabetes. Her research focuses on effective strategies to reduce blood sugar fluctuations (i.e. hypoglycemia) during exercise and in recovery in individuals with type 1 diabetes.    Dessi has been living with type 1 diabetes for over 25 years and is also an award-winning high-level athlete within Brazilian Ju-Jitsu. She understands the challenges associated with exercise and blood glucose control and is very passionate about diabetes research, specifically the body’s response to different types of physical activity.    During the episode, Dessi runs through some clinical studies and interprets insights from them to provide practical and valuable advice on various types of exercise, insulin doses, and current glucose trends.    The speakers also explore the importance of continuous glucose monitoring in managing diabetes and the role played by patient-centred care. Finally, Dessi explores how technology advancements in health care have led to the development of tools that simplify guideline applications in practical real-time scenarios. Learn how professional health care specialists like Dessi harness the knowledge gained over decades of research to ensure that it translates into ready-to-use strategies for those with diabetes. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.    Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.  The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dessi Zaharieva is a paid spokesperson for Dexcom. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe...

    40 min
  7. 01/17/2024

    CGM + GLP-1s: A Dynamic Duo for Diabetes Management

    GLP-1 medications have been around since early 2000s but only recently started getting more media coverage, thanks to celebrities and influencers. In this episode of Real-Time, Real Talk host Cher Pastore speaks to acclaimed Timothy Gilbert, MD, a clinical endocrinologist with over 15 years of experience in diabetes management. He has a practice in Louisiana where he and his team, including physicians, nurses, dieticians, and diabetes care and education specialists see many patients every day. Dr Gilbert will demystify this extremely popular weight loss drug, explain the clinical indications for use, when it is beneficial for the patient, and in what scenario GLP-1 may or may not be the best choice. Using examples from his practice, he will answer the question we all been waiting for: how does CGM and GLP-1 medication work together, and what key role CGM plays in optimizing therapy. Cher says this is her favorite episode to date, so definitely not one to be missed! Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide (https://bit.ly/3MSkRUv). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Timothy R Gilbert, MD is a paid spokesperson for Dexcom. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Dexcom Provider website: https://provider.dexcom.com/ Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

    32 min
  8. 12/20/2023

    Unleashing the Power of Partnerships: Tandem Control IQ & Dexcom G7

    In this episode of Dexcom’s Real Time Real Talk, we’re speaking to Tandem’s Medical Director, Jordan Pinkster. Jordan is a pediatric endocrinologist by training, but has been involved in clinical trials and the development of automated insulin delivery products for many years. Our second guest is Kristy Castillo, the clinical solutions manager at Tandem who is also a nurse, diabetes educator and  lives with type one diabetes herself. We’ll discuss Tandem products including the sleek new number 1 one rated AID system, the t:slim X2 insulin pump, we’ll talk about how it integrates with the Dexcom G6 and G7 and Kristy also shares her first-hand experience of using it. Finally we’ll discuss the advantages of connecting your AID system to your smartphone where possible, not just for those with diabetes but also for health care professionals.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.Dr Jordan Pinsker and Kristy Castillo are employees of Tandem Diabetes Care. About Tandem Diabetes Care: https://www.tandemdiabetes.com/en-gb/homeWarning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety...

    22 min

Ratings & Reviews

3.8
out of 5
6 Ratings

About

Welcome to “Real-time real talk,” a podcast for healthcare providers who treat people with diabetes. Each month, tune in to expert-led discussions on topics such as continuous glucose monitoring (CGM), clinical evidence for Dexcom real-time CGM, how to set up and use CGM in your practice, and real-world experiences with the Dexcom G6 CGM System. Our goal is to help you better treat your patients with type 1 and type 2 diabetes using Dexcom CGM. Real-time real talk is intended for healthcare professionals in the US.

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada